KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Net Margin (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Net Margin readings, the most recent being 34723.87% for Q4 2025.

  • On a quarterly basis, Net Margin rose 3474424.0% to 34723.87% in Q4 2025 year-over-year; TTM through Dec 2025 was 56.26%, a 7598.0% increase, with the full-year FY2025 number at 30.16%, up 4988.0% from a year prior.
  • Net Margin hit 34723.87% in Q4 2025 for Biocryst Pharmaceuticals, up from 8.09% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 34723.87% in Q4 2025 to a low of 337.29% in Q1 2021.
  • Median Net Margin over the past 5 years was 48.87% (2022), compared with a mean of 1669.35%.
  • Biggest five-year swings in Net Margin: crashed -5224bps in 2022 and later surged 3474424bps in 2025.
  • Biocryst Pharmaceuticals' Net Margin stood at 37.7% in 2021, then tumbled by -139bps to 89.94% in 2022, then grew by 27bps to 66.09% in 2023, then soared by 69bps to 20.37% in 2024, then surged by 170556bps to 34723.87% in 2025.
  • The last three reported values for Net Margin were 34723.87% (Q4 2025), 8.09% (Q3 2025), and 3.11% (Q2 2025) per Business Quant data.